SEATTLE--(BUSINESS WIRE)--Light Sciences Oncology, Inc. (LSO) today announced the closing of its latest round of funding, $30 million of its Series B preferred Stock. LSO is developing Light Infusion Therapy (Litx™) to provide safer and more effective treatment to cancer patients.
